MetLife Investment Management’s Kezar Life Sciences KZR Stock Holding History

MetLife Investment Management’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,416	Closed	-$83.7K	–	2938
2023 Q2	$83.7K	Buy	3,416 +1,609	+89%	+$41.9K	﹤0.01%	2795
2023 Q1	$56.5K	Sell	1,807 -1,002	-36%	-$58K	﹤0.01%	2706
2022 Q4	$198K	Hold	2,809	–	–	﹤0.01%	2249
2022 Q3	$242K	Buy	2,809 +795	+39%	+$77.2K	﹤0.01%	2158
2022 Q2	$167K	Hold	2,014	–	–	﹤0.01%	2439
2022 Q1	$335K	Buy	2,014 +720	+56%	+$103K	﹤0.01%	2029
2021 Q4	$216K	Hold	1,294	–	–	﹤0.01%	2004
2021 Q3	$112K	Buy	+1,294	New	+$85.6K	﹤0.01%	2395
2019 Q3	–	Sell	-694	Closed	-$53.5K	–	2363
2019 Q2	$53.5K	Hold	694	–	–	﹤0.01%	2413
2019 Q1	$123K	Buy	+694	New	+$137K	﹤0.01%	2234

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's KZR Position: Q3 2023 in Review

MetLife Investment Management sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 3,416 shares — an estimated $83.7K sold.

MetLife Investment Management first reported a position in KZR in Q1 2019 and held it in 10 quarters. The position peaked at $335K in Q1 2022. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

MetLife Investment Management reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
MetLife Investment Management sold 3,416 Kezar Life Sciences shares in Q3 2023, an estimated $83.7K.
MetLife Investment Management first reported a position in Kezar Life Sciences in Q1 2019 and held it in 10 quarters.
MetLife Investment Management's Kezar Life Sciences position peaked at $335K in Q1 2022.
82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.